Market Overview - On October 30, the Hang Seng Index fell by 0.24%, closing at 26,282.69 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 13.641 billion [1] Trading Activity - The total trading volume for the Stock Connect on October 30 was HKD 152.837 billion, with a net purchase of HKD 13.641 billion. Specifically, the Shanghai Stock Connect had a trading volume of HKD 92.627 billion and a net purchase of HKD 6.612 billion, while the Shenzhen Stock Connect had a trading volume of HKD 60.210 billion and a net purchase of HKD 7.030 billion [1] Active Stocks - In the Shanghai Stock Connect, Alibaba-W had the highest trading volume at HKD 64.51 billion, followed by SMIC and Tencent Holdings with trading volumes of HKD 52.19 billion and HKD 32.90 billion, respectively. In terms of net buying, the Yingfu Fund led with a net purchase of HKD 2.930 billion, while Alibaba-W had the highest net selling at HKD 0.386 billion [1][2] Shenzhen Stock Connect Highlights - In the Shenzhen Stock Connect, Alibaba-W also topped the trading volume with HKD 46.11 billion, followed by SMIC and Xiaomi Group with HKD 38.20 billion and HKD 24.08 billion, respectively. The Yingfu Fund recorded a net purchase of HKD 1.703 billion, while SMIC had the highest net selling at HKD 0.537 billion [2]

Group 1 - Southbound funds net bought Hong Kong stocks worth 13.641 billion HKD today [1] - The top net purchases included: - Tracker Fund of Hong Kong (46.33 million HKD) - Alibaba Group (8.75 million HKD) - Meituan (8.05 million HKD) - Hang Seng China Enterprises Index (7.72 million HKD) - CNOOC (5.74 million HKD) - Hua Hong Semiconductor (4.69 million HKD) - Xiaomi Group (2.01 million HKD) [1] - The top net sales included: - ZTE Corporation (3.23 million HKD) - Ganfeng Lithium (3.06 million HKD) - Tencent Holdings (2.64 million HKD) - Innovent Biologics (1.72 million HKD) [1] Group 2 - Southbound funds have net bought SMIC for 7 consecutive days, totaling 30.4402 million HKD [1] - Southbound funds have net bought Hua Hong Semiconductor for 4 consecutive days, totaling 19.2152 million HKD [1]

Core Insights - On October 30, 2025, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 6.451 billion, 5.219 billion, and 3.290 billion respectively [1][2] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Xiaomi Group-W (01810) also ranked as the top three, with trading amounts of 4.611 billion, 3.820 billion, and 2.408 billion respectively [1][2] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Shanghai-Hong Kong)** - Alibaba-W (09988): Trading amount of 6.451 billion, net buy of -0.386 billion - SMIC (00981): Trading amount of 5.219 billion, net buy of +0.563 billion - Tencent Holdings (00700): Trading amount of 3.290 billion, net buy of -0.310 billion - Meituan-W (03690): Trading amount of 3.203 billion, net buy of +0.535 billion - Xiaomi Group-W (01810): Trading amount of 3.070 billion, net buy of +0.456 billion [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong)** - Alibaba-W (09988): Trading amount of 4.611 billion, net buy of +1.261 billion - SMIC (00981): Trading amount of 3.820 billion, net buy of -0.537 billion - Xiaomi Group-W (01810): Trading amount of 2.408 billion, net buy of -0.254 billion - Tencent Holdings (00700): Trading amount of 2.234 billion, net buy of +0.046 billion - Huahong Semiconductor (01347): Trading amount of 2.094 billion, net buy of +0.613 billion [2]

Core Insights - Company achieved total product revenue exceeding RMB 3.3 billion in Q3 2025, reflecting a robust year-on-year growth of approximately 40% driven by both oncology and comprehensive pipelines [1][2] Group 1: Oncology Performance - Company maintains a leading position in the oncology treatment sector, with significant advantages in its product portfolio, including steady growth of key products like Dabrushe® (Sintilimab injection) [1] - Revenue contribution from innovative products has further increased, showcasing the effectiveness of the company's strategic focus [1] Group 2: Comprehensive Product Line - The comprehensive product line is rapidly releasing its potential, contributing new growth drivers with significant market access and channel marketing success for products like Xinermy® (Masitinib injection), Xinbile® (Tolebrutinib injection), and Xinbimin® (Tafasitamab N01 injection) [1] - The approval of a second diabetes indication for Masitinib injection by the National Medical Products Administration of China enhances the availability of high-quality innovative treatment options for a broader patient base [1] Group 3: Strategic Vision and Pipeline Development - Company is committed to sustainable growth and global innovation, focusing on oncology and comprehensive product lines (cardiovascular, metabolism, autoimmune, ophthalmology) [2] - As of now, the company has obtained approvals for 16 products, with 2 under review by the National Medical Products Administration, and 4 new drug molecules in Phase 3 or pivotal clinical studies, alongside approximately 15 new drug candidates in clinical research [2] - 2025 marks a significant year for the company as it enters a new phase of dual-driven growth and global innovation, progressing towards its vision of becoming a world-class biopharmaceutical company [2]

Core Insights - The company achieved total product revenue exceeding RMB 3.3 billion in Q3 2025, reflecting a robust year-on-year growth of approximately 40% driven by both oncology and comprehensive product lines [1] Oncology Sector - The company maintains a leading position in the oncology treatment field, with significant advantages in its product portfolio, including steady growth of key products like Dabu Shu (sintilimab injection) [1] - The contribution of innovative product revenue has further increased, enhancing the overall revenue mix [1] Comprehensive Product Line - The potential of the comprehensive product line is rapidly being realized, providing new growth drivers with significant revenue contributions from products like Xin Er Mei (masitinib injection), Xin Bi Le (toripalimab injection), and Xin Bi Min (tremelimumab N01 injection) [1] - Successful market access and channel marketing efforts have accelerated product uptake, leading to substantial revenue growth [1] - The second indication for masitinib for diabetes has also received approval from the National Medical Products Administration of China, expanding access to high-quality innovative treatment options for a broader patient base [1] Strategic Focus - The company is committed to sustainable growth and global innovation as its two core strategies, with a rich pipeline in oncology and comprehensive product lines (cardiovascular, metabolism, autoimmune, ophthalmology) [1] - As of now, the company has obtained approvals for 16 products, with 2 under review by the National Medical Products Administration of China, and 4 new drug molecules in Phase 3 or pivotal clinical studies, alongside approximately 15 new drug candidates in clinical research [1] - The year 2025 marks a significant milestone for the company as it enters a new phase of dual-driven growth and global innovation, progressing towards its vision of becoming a world-class biopharmaceutical company [1]

Group 1 - The core point of the article is that Innovent Biologics (01801.HK) reported a strong revenue growth of over RMB 3.3 billion in Q3 2025, reflecting approximately 40% year-on-year increase, driven by both oncology and comprehensive pipelines [1] Group 2 - The revenue growth is attributed to the dual drivers of oncology and comprehensive pipelines, indicating a robust performance in these segments [1]

Core Viewpoint - The company reported a strong revenue growth of over RMB 3.3 billion in Q3 2025, reflecting a year-on-year increase of approximately 40%, driven by both oncology and comprehensive product lines [1] Group 1: Oncology Product Performance - The company maintains a leading position in the oncology treatment sector, with significant advantages in its product portfolio, including steady growth of key products like Dabrushe® (sintilimab injection) [1] - The contribution of innovative products to revenue has further increased, showcasing the company's focus on advanced treatment options [1] Group 2: Comprehensive Product Line Development - The comprehensive product line is rapidly releasing its potential, with significant contributions from products like Xinermy® (masitinib injection), Xinbile® (toripalimab injection), and Xinbimin® (tremelimumab N01 injection), which have shown effective market access and channel marketing results [1] - The approval of a second diabetes indication for Masitinib by the National Medical Products Administration of China enhances the company's ability to provide high-quality and accessible innovative treatment solutions to a broader patient base [1] Group 3: Strategic Vision and Pipeline - The company is committed to sustainable growth and global innovation, focusing on oncology and comprehensive product lines, including cardiovascular, metabolic, autoimmune, and ophthalmology sectors [1] - As of now, the company has obtained approvals for 16 products, with 2 under review by the National Medical Products Administration of China, 4 new drug molecules in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates in clinical research [1] - The year 2025 marks a significant milestone for the company as it enters a new phase of dual-driven growth and global innovation, aiming to become a world-class biopharmaceutical company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） 內幕消息公告－2025年第三季度產品收入的最新消息 本公告由信達生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及 期貨條例第XIVA部作出。 於2025年第三季度，本公司共取得總產品收入超人民幣33億元，同比保持約40% 的強勁增長，得益於腫瘤和綜合管線雙輪驅動共同發力：1）本公司在腫瘤治療領 域保持領先地位，產品組合優勢顯著，達伯舒® （信迪利單抗注射液）等主要產品 穩健增長，創新產品收入貢獻佔比進一步提升；2）綜合產品線潛力快速釋放，貢 獻增長新驅動力：信爾美® （瑪仕度肽注射液）、信必樂® （托萊西單抗注射液）和信 必敏® （替妥尤單抗N01注射液）市場准入和渠道營銷工作成效顯著 ...

Market Overview - The Hong Kong stock market showed a mixed performance with the Hang Seng Index closing down 0.24% at 26,282.69, the Hang Seng China Enterprises Index down 0.31% at 9,346.86, and the Hang Seng Tech Index down 0.68% at 6,051.76 [1][2] - Southbound funds recorded significant net purchases exceeding 11 billion HKD, with net purchases of 6.612 billion HKD through the Shanghai-Hong Kong Stock Connect and 7.03 billion HKD through the Shenzhen-Hong Kong Stock Connect [2] Sector Performance - Large technology stocks exhibited divergent trends, with Baidu, Bilibili, and NetEase each falling over 2%, while Meituan rose over 2% [4][6] - The lithium battery sector performed strongly, with Ganfeng Lithium surging nearly 15% after reporting better-than-expected earnings [4][12] - Coal stocks, port and shipping stocks, photovoltaic stocks, nuclear power stocks, home appliance stocks, and building materials stocks were mostly active [4] Notable Stocks - Ganfeng Lithium reported a revenue of 14.625 billion CNY for the first three quarters of 2025, a year-on-year increase of 5.02%, and a net profit of 25.52 million CNY, recovering from a loss of 640 million CNY in the previous year [12] - In the healthcare sector, innovative drug stocks declined, with companies like Xiansheng Pharmaceutical and Innovent Biologics dropping over 4% [9] - Real estate stocks faced downward pressure, with China Overseas Macro Group and R&F Properties falling 5% [10] Commodity Performance - Gold and precious metals saw significant gains, with companies like Zijin Mining and China Silver Group rising over 8% [11] - The World Gold Council reported a 3% year-on-year increase in global gold demand for Q3 2025, reaching 1,313 tons, marking the highest quarterly demand on record [11] Economic Outlook - Morgan Asset Management indicated that a moderate expansion of the U.S. economy and gradually declining interest rates could benefit risk assets, particularly in the technology, communication services, and financial sectors [14] - The Federal Reserve's interest rate cuts are expected to enhance global liquidity, potentially supporting non-U.S. markets [14]

Core Insights - The core focus of the news is on the strategic collaboration between Innovent Biologics and JD Health, highlighting Innovent's product pipeline and growth targets, particularly in the area of weight management drugs [1][3][4]. Company Overview - Innovent Biologics has 16 products on the market, making it the Chinese company with the most marketed monoclonal antibody products. The company has benefited 5 million patients and has 21 clinical pipelines with 140,000 liters of operational capacity [1]. - The company aims to commercialize 17 products by 2025 and achieve positive EBITDA, with a target of 20 commercialized products and revenue of 20 billion RMB by 2027 [1]. Product Development - Innovent's weight management drug, the first global GCG/GLP-1 dual receptor agonist, was approved for market in June 2023, marking a significant milestone in the company's innovation efforts [1][3]. - The drug, named "信尔美" (Masitide), was launched on JD Health's platform shortly after approval, attracting over 30,000 users in the first month and achieving over 1 million searches on JD's platform within a month [3]. Strategic Collaboration - The partnership with JD Health leverages three core advantages: strong supply chain capabilities, a large user base, and digital marketing expertise [4]. - JD Health's logistics management ensures safe and compliant delivery of temperature-sensitive medications, with nationwide cold chain storage capabilities [4][5]. Market Reach and Services - JD Health has launched an online "Weight Management Clinic" to address various health needs related to weight issues, integrating multidisciplinary resources including top-tier doctors and nutritionists [5]. - The platform has over 10,000 online pharmacists and an AI pharmacist named "Xiao Fang," providing 24/7 medication guidance and enhancing patient adherence to medication [5]. Logistics and Delivery - JD Logistics has invested in specialized cold chain equipment to ensure the safe transport of medications, maintaining a temperature range of 2-8°C for up to 72 hours [6]. - The company has established 33 drug warehouses nationwide, ensuring over 90% of orders can be delivered on the same or next day, with rapid delivery options for temperature-sensitive drugs [5][6].